New Delhi: The country's pharmaceutical market will see continued strong growth at a more favourable rate than its global peers and even if the country's GDP growth were to slow down, it would still represent a better growth opportunity, according to Moody's Investors Service.
Stressing on the potential of the sector, Moody's Vice President and Senior Analyst Kailash Chhaya said: "Even if India's GDP growth slows or is uneven, the Indian pharmaceutical market would still represent a better growth opportunity than many other geographic markets..."
This is due to improving socio-economic conditions and access to healthcare against the backdrop of a rising prevalence of diseases such as diabetes and cardiovascular problems, he added.
The sector would also witness heightened activity of mergers and acquisitions (M&A) following global trend although Indian firms do not face the same growth pressures as other players across the industry, MIS said. "As consolidation in the industry continues globally, particularly among generic drug companies, Indian firms will increasingly look to become involved in global mergers and acquisitions. We have already seen some Indian companies increasing their pace of acquisitions," Moody's Senior Vice President Michael Levesque said.
The M&A activity could pressurise Indian firms' leverage from currently low levels, MIS added. "However, for most Indian companies, debt headroom is large as balance sheets are generally lowly leveraged," the MIS report said.